Watson reaches patent settlement for Actos generic
MORRISTOWN, N.J. Watson Pharmaceuticals and Takeda Pharmaceuticals North America have settled a patent litigation case concerning a diabetes drug, Watson announced Wednesday.
The generic drug maker said Takeda granted it a non-exclusive, royalty-free license to its patents covering Actos (pioglitazone hydrochloride), an oral treatment for Type 2 diabetes, in the 15-mg, 30-mg and 45-mg strengths.
Under the agreement, Watson will be allowed to launch its generic Actos in August 2012. The patents covering the drug expire in 2016, according to the Food and Drug Administration.
Actos had sales of $3.4 billion in 2009, according to IMS Health.